Clinical Trial: Chemotherapy Exemption in Elderly Women With Node-Positive ER+/HER2- Breast Cancer

U.S., Sept. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07826052) titled 'Chemotherapy Exemption in Elderly Women With Node-Positive ER+/HER2- Breast Cancer' on Sept. 12.

Brief Summary: This study is a prospective, open-label, multicenter, single-arm Phase II clinical trial. Based on the use of CDK4/6 inhibitors in endocrine-sensitive luminal-type (ER+/HER2-) breast cancer, it aims to explore the possibility of chemotherapy exemption in elderly patients (aged >65 years) with lymph node-positive, HR+/HER2- breast cancer.

Study Start Date: Sept. 15

Study Type: INTERVENTIONAL

Condition: Breast Cancer Adjuvant Therapy

Intervention: DRUG: CDK4/6 inhibitor

(abemaciclib/ribociclib/dalpiciclib/palbociclib...